GlaxoSmithKline Pharmaceuticals Limited has announced a board meeting on the financial results for the quarter and half-year.

At the 100th Annual General Meeting, key resolutions were approved, including adoption of audited financial statements, declaration of a final dividend of Rs 42 per share, re-appointment of Mr. Juby Chandy as Director, re-appointment of Dr. Sunita Maheshwari as Independent Director, appointment of Parikh & Associates as Secretarial Auditors, and ratification of remuneration to the Cost Auditors.

All resolutions passed with overwhelming shareholder approval.

No operational or business changes were reported.